Rubin Lab

RECENT LAB PUBLICATIONS

Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data from a Large Tertiary Center​.

Cohen NA, Choi D, Choden T, Krugliak Cleveland N, Cohen RD, Rubin DT. Clin Gastroenterol Hepatol. 2022. [Epub ahead of print April 2 2022]. PMID: 35381385.

Upadacitinib Is Safe and Effective for Crohn’s Disease: Real-World Data from a Tertiary Center.

Traboulsi C, Ayoub F, Silfen A, Rodriguez TG, Rubin DTDig Dis Sci. 2022. [Epub ahead of print June 13 2022]. PMID: 35695972.

Long-Term Outcomes of the Excluded Rectum in Crohn’s Disease: A Multicenter International Study.

Kassim G, Yzet C, Nair N, Debebe A, Rendon A, Colombel JF, Traboulsi C, Rubin DT, Maroli A, Coppola E, Carvello MM, David NB, De Lucia F, Sacchi M, Danese S, Spinelli A, Hirdes MMC, Ten Hove J, Oldenburg B, Cholapranee A, Riter M, Lukin D, Scherl E, Eren E, Sultan KS, Axelrad J, Sachar DB. Inflamm Bowel Dis. 2022. [Epub ahead of print May 6 2022]. PMID: 35522225.

Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus.

Ananthakrishnan AN, Kaplan GG, Bernstein CN, Burke KE, Lochhead PJ, Sasson AN, Agrawal M, Tuan Tiong JH, Steinberg J, Kruis W, Steinwurz F, Ahuja V, Ng SC, Rubin DT, Colombel JF, Gearry R, International Organization for Study of Inflammatory Bowel Diseases. Lancet Gastroenterol Hepatol. 2022. In Press. PMID: 35487235.

HTML

 

What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented?​.

Krugliak Cleveland N, Torres J, Rubin DT. Gastroenterology. 2022;162(5):1396-1408. PMID: 35101421.

Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study.

Sandborn WJ, D’Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, Weisel K, Germinaro M, Frustaci ME, Yang Z, Adedokun OJ, Han C, Panaccione R, Hisamatsu T, Danese S, Rubin DT, Sands BE, Afzali A, Andrews JM, Feagan BG, GALAXI-1 Investigators. Gastroenterology. 2022;162(6):1650-1664. PMID: 35134323.

The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease.

Anyane-Yeboa A, Quezada S, Rubin DT, Balzora S. Clin Gastroenterol Hepatol. 2022. In Press. PMID: 35307597.

Assessment of the Degree of Variation of Histologic Inflammation in Ulcerative Colitis​.

Mikolajczyk AE,Cohen N, Watson S, Ackerman M, Goeppinger SR, Hart J, Turner JR, Rubin DT. Inflamm Bowel Dis. 2022. [Epub ahead of print April 18 2022]. PMID: 35436339.

Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey​.

Parigi TL, D’Amico F, Abreu MT, Dignass A, Dotan I, Jairath V, Magro F, Rubin DT, Peyrin-Biroulet L, Ghosh S, Danese S. Lancet Gastroenterol Hepatol. 2022;7(5):390-391. PMID: 35397241.

IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus​.

Caron B, Abreu MT, Siegel CA, Panaccione R, Sands BE, Dignass A, Turner D, Dotan I, Hart AL, Ahuja V, Allez M, Ananthakrishnan AN, Ghosh S, Griffiths AM, Halfvarson J, Kaser A, Kotze PG, Koutroubakis IE, Lakatos PL, Levine A, Lewis JD, Magro F, Mantzaris GJ, O’Morain C, Ran Z, Reinisch W, Rogler G, Sachar DB, Siegmund B, Silverberg MS, Sood A, Spinelli A, Steinwurz F, Tysk C, Yamamoto-Furusho JK, Schreiber S, Rubin DT, Sandborn WJ, Danese S, Peyrin-Biroulet L. Clin Gastroenterol Hepatol. 2022. [Epub ahead of print February 19 2022]. PMID: 35189386.